PYXS News and Press, Pyxis Oncology Inc. From 05/13/22

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Co...

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, ...

Gainers: Pyxis Oncology (PYXS) +14%. SVB Financial Group (SIVB) +11%. Adaptive Biotechnologies Corporation (ADPT) +6%. Taboola  (TBLA) +6%. UFP Industries(UFPI) +5%. Losers: SCYNEXIS (SCYX) -21%. Corsair Gaming (CRSR) -13%. LifeMD (LFMD) -9%. Clarus Therapeutics ...

- Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer - - Jan Pinkas, Ph.D., promoted to Chief Scientific Officer - - Company continues to advance programs toward the clinic with IND filings for Anti-EDB, PYX-201, and Anti-Siglec-15, PYX-106, expect...

- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncolo...

RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agree...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Biosion is granting Pyxis Oncology (NASDAQ:PYXS) an exclusive license to develop and commercialize its monoclonal antibody BSI-060T. Pyxis will pay $10M upfront to Biosion for a worldwide license, except in Greater China, for developing and selling BSI-060T (now referred to as PYX-106). ...

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology PR Newswire - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $1...

Pyxis Oncology press release (NASDAQ:PYXS): FY GAAP EPS of -$8.95 misses by $5.88. As of March 29, 2022, cash and cash equivalents of approximately $253M For further details see: Pyxis Oncology GAAP EPS of -$8.95 misses by $5.88